Cargando…

Pharmacokinetic profile of an intradeltoid diclofenac injection in obese Indian volunteers

BACKGROUND: A new propylene glycol-free and reduced-volume formulation of diclofenac sodium 75 mg/mL designed for intradeltoid administration has been found to be bioequivalent to a reference formulation of diclofenac sodium 75 mg/3 mL given via the intragluteal route in normal healthy volunteers. S...

Descripción completa

Detalles Bibliográficos
Autores principales: Shep, Dhaneshwar, Ojha, Ashwini, Patel, Sweta, Nivsarkar, Manish, Jaiswal, Vijaya, Padh, Harish
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033031/
https://www.ncbi.nlm.nih.gov/pubmed/21311716
http://dx.doi.org/10.2147/JPR.S13894
_version_ 1782197529075515392
author Shep, Dhaneshwar
Ojha, Ashwini
Patel, Sweta
Nivsarkar, Manish
Jaiswal, Vijaya
Padh, Harish
author_facet Shep, Dhaneshwar
Ojha, Ashwini
Patel, Sweta
Nivsarkar, Manish
Jaiswal, Vijaya
Padh, Harish
author_sort Shep, Dhaneshwar
collection PubMed
description BACKGROUND: A new propylene glycol-free and reduced-volume formulation of diclofenac sodium 75 mg/mL designed for intradeltoid administration has been found to be bioequivalent to a reference formulation of diclofenac sodium 75 mg/3 mL given via the intragluteal route in normal healthy volunteers. Standard needles may not reach the gluteus maximus muscle in many cases, especially in the obese. The objective of this study was to determine the pharmacokinetic parameters of the new formulation and compare the bioavailability of intradeltoid diclofenac sodium 75 mg/mL with that of the intragluteal 75 mg/3 mL reference formulation in obese volunteers. METHODS: A comparative, two-way, single-dose, bioavailability study was carried out in 10 obese (body mass index > 25) male Indian volunteers after a washout period of seven days. Blood samples were collected until six hours following drug administration and analyzed using a prevalidated high-pressure liquid chromatography method. RESULTS: The mean maximum plasma concentration and time to reach maximum plasma concentration for the test formulation were 1.30 μg/mL and 0.50 hours, respectively, versus 0.93 μg/ mL and 1.08 hours for the reference formulation. The mean areas under the curve from 0 to last measurable time point (AUC(0–t)) for the test and reference formulations were 2.71 μg·h/mL and 2.73 μg·h/mL, respectively. The mean AUCs from 0 to infinity (AUC(0–∞)) for the test and reference formulations were 3.71 μg·h/mL and 3.75 μg·h/mL, respectively. CONCLUSION: The results suggest that the test formulation of diclofenac sodium 75 mg/mL has an AUC(0–t) and AUC(0–∞) comparable with the reference intragluteal formulation of diclofenac sodium 75 mg/3 mL, but with an earlier time to reach maximum plasma concentration and a trend towards a higher maximum plasma concentration. This could be attributed to faster absorption from the deltoid region than from the gluteal region. The test formulation could be helpful in the management of pain in obese or overweight patients and those with dense subcutaneous fat in the gluteal area.
format Text
id pubmed-3033031
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-30330312011-02-10 Pharmacokinetic profile of an intradeltoid diclofenac injection in obese Indian volunteers Shep, Dhaneshwar Ojha, Ashwini Patel, Sweta Nivsarkar, Manish Jaiswal, Vijaya Padh, Harish J Pain Res Original Research BACKGROUND: A new propylene glycol-free and reduced-volume formulation of diclofenac sodium 75 mg/mL designed for intradeltoid administration has been found to be bioequivalent to a reference formulation of diclofenac sodium 75 mg/3 mL given via the intragluteal route in normal healthy volunteers. Standard needles may not reach the gluteus maximus muscle in many cases, especially in the obese. The objective of this study was to determine the pharmacokinetic parameters of the new formulation and compare the bioavailability of intradeltoid diclofenac sodium 75 mg/mL with that of the intragluteal 75 mg/3 mL reference formulation in obese volunteers. METHODS: A comparative, two-way, single-dose, bioavailability study was carried out in 10 obese (body mass index > 25) male Indian volunteers after a washout period of seven days. Blood samples were collected until six hours following drug administration and analyzed using a prevalidated high-pressure liquid chromatography method. RESULTS: The mean maximum plasma concentration and time to reach maximum plasma concentration for the test formulation were 1.30 μg/mL and 0.50 hours, respectively, versus 0.93 μg/ mL and 1.08 hours for the reference formulation. The mean areas under the curve from 0 to last measurable time point (AUC(0–t)) for the test and reference formulations were 2.71 μg·h/mL and 2.73 μg·h/mL, respectively. The mean AUCs from 0 to infinity (AUC(0–∞)) for the test and reference formulations were 3.71 μg·h/mL and 3.75 μg·h/mL, respectively. CONCLUSION: The results suggest that the test formulation of diclofenac sodium 75 mg/mL has an AUC(0–t) and AUC(0–∞) comparable with the reference intragluteal formulation of diclofenac sodium 75 mg/3 mL, but with an earlier time to reach maximum plasma concentration and a trend towards a higher maximum plasma concentration. This could be attributed to faster absorption from the deltoid region than from the gluteal region. The test formulation could be helpful in the management of pain in obese or overweight patients and those with dense subcutaneous fat in the gluteal area. Dove Medical Press 2010-11-19 /pmc/articles/PMC3033031/ /pubmed/21311716 http://dx.doi.org/10.2147/JPR.S13894 Text en © 2010 Shep et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Shep, Dhaneshwar
Ojha, Ashwini
Patel, Sweta
Nivsarkar, Manish
Jaiswal, Vijaya
Padh, Harish
Pharmacokinetic profile of an intradeltoid diclofenac injection in obese Indian volunteers
title Pharmacokinetic profile of an intradeltoid diclofenac injection in obese Indian volunteers
title_full Pharmacokinetic profile of an intradeltoid diclofenac injection in obese Indian volunteers
title_fullStr Pharmacokinetic profile of an intradeltoid diclofenac injection in obese Indian volunteers
title_full_unstemmed Pharmacokinetic profile of an intradeltoid diclofenac injection in obese Indian volunteers
title_short Pharmacokinetic profile of an intradeltoid diclofenac injection in obese Indian volunteers
title_sort pharmacokinetic profile of an intradeltoid diclofenac injection in obese indian volunteers
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033031/
https://www.ncbi.nlm.nih.gov/pubmed/21311716
http://dx.doi.org/10.2147/JPR.S13894
work_keys_str_mv AT shepdhaneshwar pharmacokineticprofileofanintradeltoiddiclofenacinjectioninobeseindianvolunteers
AT ojhaashwini pharmacokineticprofileofanintradeltoiddiclofenacinjectioninobeseindianvolunteers
AT patelsweta pharmacokineticprofileofanintradeltoiddiclofenacinjectioninobeseindianvolunteers
AT nivsarkarmanish pharmacokineticprofileofanintradeltoiddiclofenacinjectioninobeseindianvolunteers
AT jaiswalvijaya pharmacokineticprofileofanintradeltoiddiclofenacinjectioninobeseindianvolunteers
AT padhharish pharmacokineticprofileofanintradeltoiddiclofenacinjectioninobeseindianvolunteers